Schedule 13G ownership disclosure
X4 PHARMACEUTICALS INC
Common Stock, par value $0.001 per share · CUSIP: 98420X103
Event date: 2025-06-30
- Filing-level shares
- 134,947.00
- Percent of class
- 1.7%
- ORBIMED ADVISORS LLC
Shares: 134,947.00 · Class: 1.7%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000947871-25-000777
- Form type
- SCHEDULE 13G/A
- Filer
- ORBIMED ADVISORS LLC
- CIK
- CIK 1055951
- Filed
- Aug 14, 2025
- Reporting period
- Jun 30, 2025
- Description
- Schedule 13G beneficial ownership